Jeenah Moon/Getty Images News
Pfizer (NYSE:PFE) shares traded higher in the premarket on Tuesday after the New York-based pharma giant reported better-than-expected financials for Q2 2025 and increased its full-year earnings outlook, citing, among other things, its strong YTD performance.
The company reported $14.7B in revenue for the quarter with a ~10% YoY growth, exceeding the consensus by $1.1B as its primary care business, led by its COVID franchise, outperformed, generating $5.5B to the topline with a ~12% YoY growth.
Pfizer’s (NYSE:PFE) COVID shot Comirnaty, developed with BioNTech (BNTX), added $381M to the topline with ~96% YoY growth, thanks mainly to higher U.S. net revenues while beating the $193.7M projected by analysts, according to Bloomberg data.
Meanwhile, its COVID pill Paxlovid added $427M in revenue with ~70% YoY growth, exceeding the $238.4M in the consensus, and PFE’s Prevnar family of pneumonia vaccines brought $1.4B globally with ~2% YoY growth, roughly in line with the consensus.
As for other drugs, blood thinner Eliquis, developed with Bristol Myers (BMY), generated $2.0B with ~7% YoY growth compared to $1.9B projected by analysts, and sales from the company’s cancer drug Ibrance fell ~6% YoY to ~$1.05B still ahead of $1.02B in the consensus.
While Pfizer (NYSE:PFE) reaffirmed its full-year revenue outlook at $61.0B–$64.0B, its new earnings outlook at $2.90–$3.10 per-share, increased by $0.10 at the midpoint on an adjusted basis, stood in line with $3.01 in the consensus.
“We raised our full-year 2025 Adjusted diluted EPS guidance, demonstrating confidence in our ability to execute against our strategic priorities and deliver strong results for shareholders,” CFO David Denton remarked.
Edmund Ingham, Investing Group Leader for Haggerston BioHealth, welcomed the Street’s initial reaction to Pfizer (NYSE:PFE) results.
“Q2 revenues were up by a double-digit percentage, to $14.7B and FY revenue guidance for more than $61B revenues has been upheld, and for EPS of $3 at the midpoint, reflecting a single-digit forward P/E of less than 10x, arguably a strong buy signal,” he wrote.
“This latest set of earnings, and Wall Street’s response, will give investors genuine confidence that Pfizer’s business, and stock price, is now entering a period of long-term growth.”